30 closest matches · ranked by relevance
Atherogenic Dyslipidemia · Obesity Associated Disorder
Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001
Dyslipidemias · Cardiovascular Diseases · Hypertriglyceridemia
Primary: Percentage of Triglyceride (TG) Change — -38.12 percentage of TG change
Non-alcoholic Fatty Liver Disease (NAFLD)
Primary: Production Rate of VLDL-1 Triacylglycerol (TAG) — 20.9; 18.9; 16.6; 12.4 grams/day — p=<0.05
Dyslipidemias · Hypercholesterolemia · Hypertriglyceridemia
Primary: Total Cholesterol (TC) Levels at First Acute Coronary Event — 163.5 mg/dL
Hyperlipidemia, Periodontitis, Gingivitis
Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml
Type 2 Diabetes Mellitus
Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001
Dyslipidemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 — -31.19; -33.83; -41.09; -46.62 Percent Change (%) — p=< 0.001
Dyslipidaemia
Primary: Change in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12. — 0.978; 0.206; 0.270; 0.606 Ratio
Dyslipidemia
Primary: Percent Changes From Baseline to End-of-treatment in Non-HDL Cholesterol, HDL Cholesterol, and Triglycerides by LCP-AtorFen Versus Atorvastatin Monotherapy — -44.8…
Dyslipidemia
Primary: Total Cholesterol Before and After Simvastatin/Ezetimibe Administration — 255; 253; 180; 215 mg/dl — p=<0.05
Dyslipidemia · Cardiovascular Diseases · Hypercholesterolemia
Primary: Mean Low Density Lipid-Cholesterol (LDL-C) Levels in High and Very High Risk Cardiovascular Participants — 2.40; 1.99 mmol/L
Lipid Metabolism Disorders
Primary: Cholesterol Efflux Capacity (CEC) — 1.30; 0.65 Ratio
Metabolic Syndrome X
Primary: Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions — 110531; 95140 #copies/100000 copies housekeeping gene
Mixed Dyslipidemia
Primary: Triglycerides After 90 Days — 2.3; 1.1; 1.3 mmol/L
Type 2 Diabetes Mellitus
Primary: Increased HDL-Cholesterol and Decreased Triglycerides — 7.9; 2.7; 15.7; -1.5 % Change — p=0.05
Hypertriglyceridemia · Atherosclerotic Cardiovascular Disease · Severe Hypertriglyceridemia
Primary: Percent Change From Baseline in Fasting TG at Month 6 — -7.77; -57.05; -60.92 Percent Change — p=<0.0001
Hyperlipidemia
Primary: Myocardial Perfusion at Rest — 55; 135 IU/s
Type 2 Diabetes · Hypertension
Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg
Mixed Dyslipidemia
Primary: Percent Change From Baseline at Week 24 in Fasting TG — -1.7; -51.5; -57.7; -64.1 percentage change — p=<0.0001
Metabolic Syndrome
Primary: Mean Low Density Lipoprotein Cholesterol in Blood — 70; 135 mg/dl
Diabetic Retinopathy · Dyslipidemia
Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr
Dyslipidemias · Lipid Metabolism Disorders · Metabolic Diseases
Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691
Dyslipidemia
Primary: Mean Change in Calculated Low Density Lipoprotein Cholesterol — -22.7 mg/dL — p=0.0042
Type2 Diabetes
Primary: Lipoprotein-associated Phospholipase A2 — 238.4 ng/ml
Primary Hyperlipidemia and Mixed Dyslipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR) — -5.07; 74.13; 83.70; 310.48 percent change — p=0.018
Familial Partial Lipodystrophy
Primary: Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27) — -59.9 percent change
Hypercholesterolemia · Hyperlipoproteinemia Type II
Primary: Number of Participants Who Incurred at Least One Treatment Emergent Event — 33; 10 participants
Homozygous Familial Hypercholesterolemia
Primary: Number of LDLR Gene Mutations — 7 gene mutations
Metabolic Syndrome
Primary: Ex Vivo Effects of Treatment With Vytorin Versus Zocor for 6 Weeks on Platelet Alpha Thrombin PAR-1 Receptor Expression — 35.4; 34.5; 23.6; 22.5 ng/dl
Insulin Resistance · Hypertriglyceridemia
Primary: Pre- and Post-Intervention Triglyceride Levels — 231; 209; 201; 140 mg/dL